Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 12;13:983313. doi: 10.3389/fimmu.2022.983313

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Mayer-Blackwell, Johnson, Potchen, Minot, Heptinstall, Seaton, Sawant, Shen, Tomaras, Fiore-Gartland and Kublin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Participant-matched anti-gp41 IgG (MFI) pre- vs. post-vaccine for participants receiving either (A) vaccines containing gp41 immunogens or (B) vaccines lacking gp41 immunogens. Consistency in response magnitude in panel (B), among participants receiving vaccines without gp41, shows the temporal stability of participants’ anti-gp41 cross-reactive response between measurements collected 26-52 weeks apart. The dashed 1:1 line represents no change between pre- and post-timepoints. T1-T5 indicates specific variation in vaccine dose regimen within a particular trial. Within each trial the nature of the gp41 immunogen was consistent across regimens.